002675 东诚药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入626,367-8.82%2,741,0742,868,9373,275,6483,582,955
减:营业总成本577,284-9.48%2,521,6982,649,0522,826,4773,034,645
    其中:营业成本293,569-21.82%1,344,0491,516,5291,805,9582,044,375
               财务费用42,25976.65%146,99477,23431,2936,151
               资产减值损失------(83,875)(111,886)(80,290)
公允价值变动收益179-49.87%9051,068(19,474)401
投资收益1,470-190.93%(16,781)(13,985)(8,654)(39,614)
    其中:对联营企业和合营企业的投资收益(35)-99.10%(24,039)(25,289)(37,751)(41,716)
营业利润48,58537.67%212,639220,806341,662448,252
利润总额48,40638.89%211,443219,103337,282445,576
减:所得税费用13,539-23.52%57,00177,67883,06592,749
净利润34,867103.31%154,441141,425254,216352,828
减:非控股权益1,432-118.88%(41,188)(42,401)44,48145,536
股东净利润33,43535.19%195,629183,826209,736307,291

市场价值指针
每股收益 (元) *0.04135.00%0.2370.2230.2540.380
每股派息 (元) *----0.0810.0800.1250.150
每股净资产 (元) *5.198-4.65%5.2755.4345.7915.759
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容